Welcome to our dedicated page for SAB BIOTHERAPEUTICS SEC filings (Ticker: SABS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SAB Biotherapeutics, Inc. (SAB BIO) SEC filings page for ticker SABS provides access to the company’s official regulatory disclosures as a clinical-stage biopharmaceutical issuer on Nasdaq. These documents are a primary source for detailed information on SAB BIO’s governance, equity structure, and other material corporate events related to its development of fully human immunoglobulin G (hIgG) and human anti-thymocyte immunoglobulin (hATG) therapies, including its lead program SAB-142 for autoimmune type 1 diabetes.
In SAB BIO’s Form 8-K filings, investors can find reports on matters such as Board of Directors changes and stockholder approvals. For example, one 8-K describes the resignation of two directors and a reduction in the size of the Board, noting that the departures were not due to disagreements over company operations, policies, or practices. Another 8-K details the results of a special meeting of stockholders, where stockholders approved amendments to the 2021 Omnibus Equity Incentive Plan, including increases in the maximum number of shares available under the plan and adjustments to the plan’s evergreen share increase, as well as approval of a proposal related to potential issuance of common stock upon conversion of Series B Convertible Preferred Stock under Nasdaq rules.
On Stock Titan, these and other SAB BIO filings are updated from the SEC’s EDGAR system and can be reviewed alongside AI-powered summaries. AI analysis helps explain complex items such as equity plan amendments, preferred stock conversion terms, and governance changes in clear language, saving time when reading lengthy forms. Users can quickly identify key sections of 8-Ks, 10-Ks, and 10-Qs, and can also monitor how equity incentives and capital structure decisions may relate to the company’s ongoing clinical development of SAB-142 and its broader human IgG platform.
For those researching SABS, this page centralizes SAB Biotherapeutics’ historical and current SEC reports, with tools to interpret the implications of each filing without manually parsing every line of legal and accounting text.
SAB Biotherapeutics, Inc. director Jay S. Skyler reported receiving a stock option grant as part of his 2025 annual compensation for serving on the board. On 12/16/2025, he was granted an option to purchase 150,000 shares of common stock at an exercise price of $3.99 per share.
The option was issued under the company’s 2021 Omnibus Equity Incentive Plan, as amended. The shares underlying this option vest in two equal annual installments on December 16, 2026 and December 16, 2027, meaning the director earns the right to exercise half the options on each of those dates if service conditions are met.
SAB Biotherapeutics, Inc. reported an equity award to director William James Polvino. On December 16, 2025, he received a stock option covering 150,000 shares of common stock at an exercise price of $3.99 per share. This grant represents his 2025 annual compensation as a member of the Board of Directors. The option vests in two equal installments on December 16, 2026 and December 16, 2027, meaning he earns the right to exercise half the option on each of those dates. The award was granted under the company’s 2021 Omnibus Equity Incentive Plan, as amended.
SAB Biotherapeutics, Inc. disclosed that a director received a new stock option grant as part of 2025 board compensation. On December 16, 2025, the director was granted a stock option to purchase 150,000 shares of common stock at an exercise price of $3.99 per share, expiring on December 16, 2035. The filing shows the director beneficially owning 150,000 derivative securities directly after this transaction.
According to the disclosure, this grant represents the director’s 2025 annual grant for board service. The shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027. The award was made under the company’s 2021 Omnibus Equity Incentive Plan, as amended, which governs how equity-based compensation is issued to eligible participants.
SAB Biotherapeutics, Inc. reported an insider equity award for director Katie Ellias. She received a stock option to buy 150,000 shares of common stock at an exercise price of $3.99 per share, dated December 16, 2025, under the company’s 2021 Omnibus Equity Incentive Plan. The grant is described as her 2025 annual award for service on the Board of Directors.
The shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027, and the option expires on December 16, 2035. Following this grant, she beneficially owns 150,000 derivative securities directly, all tied to this stock option award.
SAB Biotherapeutics, Inc. reported a new stock option award to one of its directors, Scott Giberson. On 12/16/2025, he received a stock option (right to buy) covering 150,000 shares of the company’s common stock with an exercise price of $3.99 per share, expiring on 12/16/2035.
The filing states this is the director’s 2025 annual grant for service on the Board of Directors. The options vest in two equal annual installments on December 16, 2026 and December 16, 2027, and were granted under SAB Biotherapeutics’ 2021 Omnibus Equity Incentive Plan, as amended.
SAB Biotherapeutics director reports new stock option grant. A member of the Board of Directors received a stock option covering 150,000 shares of SAB Biotherapeutics, Inc. common stock on 12/16/2025 at an exercise price of $3.99 per share. The option expires on 12/16/2035 and represents the director’s 2025 annual equity grant. The underlying shares vest in two equal annual installments on December 16, 2026 and December 16, 2027. The award was granted under the company’s 2021 Omnibus Equity Incentive Plan, as amended, and is held directly by the reporting person.
SAB Biotherapeutics, Inc. filed a Form S-8 registration statement to register 24,180,000 additional shares of common stock for issuance under its 2021 Omnibus Equity Incentive Plan, as amended.
The registration covers the same class of securities as earlier S-8 statements and incorporates the company’s latest annual, quarterly, and current reports by reference, so the equity compensation plan remains supplied with stock for future grants to eligible participants.
SAB Biotherapeutics, Inc. reported an insider equity transaction by its Chief Medical Officer, Alexandra Kropotova. On 12/11/2025, 988 shares of common stock were withheld to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock units (RSUs).
After this transaction, Kropotova beneficially owned a total of 44,284 shares of common stock. This amount includes 31,946 shares of common stock and 12,338 shares that remain subject to vesting of RSUs granted under the company’s 2021 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock.
SAB Biotherapeutics, Inc. reported Q3 results showing a swing to net income, driven by non‑cash warrant valuation effects and a mid‑year capital raise. For the quarter, the company recorded net income of $45.4 million, while operating activities remained in investment mode with loss from operations of $12.7 million as R&D and G&A totaled $12.7 million. No revenue was recognized in the period.
The balance sheet strengthened markedly. As of September 30, 2025, cash and cash equivalents were $29.4 million, with short‑term investments of $81.5 million and long‑term investments of $50.6 million. Total assets rose to $183.4 million and stockholders’ equity to $165.1 million, reflecting proceeds from the 2025 private placement and equity reclassifications. The quarter included a $61.6 million gain from changes in fair value of warrant liabilities and $4.9 million of warrant issuance costs.
Year to date, net cash used in operations was $28.0 million, offset by $168.7 million provided by financing activities from the 2025 PIPE. The company noted existing resources are sufficient to cover operating cash needs for the twelve months following the report date. Common shares outstanding were 47,606,851 as of November 10, 2025.
FAQ
What is the current stock price of SAB BIOTHERAPEUTICS (SABS)?
What is the market cap of SAB BIOTHERAPEUTICS (SABS)?
